Prevalence of Fabry Disease in Female Patients With Late-Onset Hypertrophic Cardiomyopathy

Abstract

FD may account for up to 12% of females with late-onset HCM. Those heterozygous for FD with left ventricular hypertrophy are potential candidates for enzyme enhancement/replacement therapy.